Ipsen to acquire Kartos Therapeutics for up to $1.75bn
Global biopharmaceutical company Ipsen is to acquire California-based clinical-stage biopharmaceutical company Kartos Therapeutics in a transaction valued at up to $1.75bn. The deal involves an upfront cash payment of $450m, with a further $1.3bn tied to the achievement of regulatory and commercial milestones. This transaction is expected to close in the third quarter of 2026 and highlights Ipsen’s continued focus…